Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States

Published:2024-02 Issue:2 Volume:27 Page:164-172
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Carlson Josh,Foos Volker,Kasle Adam,Mugwagwa Tendai,Draica Florin,Lee Wiemken Timothy,Nguyen Jennifer L.,Cha-Silva Ashley,Migliaccio-Walle Kristen,Dzingina Mendy

Funder

Pfizer Inc

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference27 articles.

1. An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment;Drożdżal;Drug Resist Updat,2021

2. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19;Hammond;N Engl J Med,2022

3. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system;Lewnard;Lancet Infect Dis,2023

4. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019;Ganatra;Clin Infect Dis,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 therapeutics;Clinical Microbiology Reviews;2024-06-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP